Evidence map›Paper›PMID 39862333›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2025

Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer's disease using ADNI.

Marwa E Elhefnawy, Noel Patson, Samer Mouksassi, Goonaseelan Pillai, Sergey Shcherbinin, Emmanuel Chigutsa, Ivelina Gueorguieva

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Donanemab exposure-response in early symptomatic Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marwa E ElhefnawyApplied Pharmacometrics Training-Africa Program, c/o Pharmacometrics Africa NPC, Cape Town, South Africa.
Noel PatsonApplied Pharmacometrics Training-Africa Program, c/o Pharmacometrics Africa NPC, Cape Town, South Africa.
Samer MouksassiApplied Pharmacometrics Training-Africa Program, c/o Pharmacometrics Africa NPC, Cape Town, South Africa.
Goonaseelan PillaiApplied Pharmacometrics Training-Africa Program, c/o Pharmacometrics Africa NPC, Cape Town, South Africa.
Sergey ShcherbininEli Lilly and Company, 16 893 South Delaware Street, Indianapolis, IN, USA.
Emmanuel ChigutsaEli Lilly and Company, 16 893 South Delaware Street, Indianapolis, IN, USA.
Ivelina GueorguievaGlobal PK/PD/PMx, Eli Lilly and Company, 8 Arlington Square West, Downshire Way, Bracknell, Berkshire, RG12 1PU, UK. gueorguieva_ivelina@lilly.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain amyloid beta neuritic plaque accumulation is associated with an increased risk of progression to Alzheimer's disease (AD) [Pfeil, J., et al. in Neurobiol Aging 106: 119-129, 2021]. Several studies estimate rates of change in amyloid plaque over time in clinically heterogeneous cohorts with different factors impacting amyloid plaque accumulation from ADNI and AIBL [Laccarino, L., et al. in Annals Clin and Trans Neurol 6: 1113 1120, 2019, Vos, S.J., et al. in Brain 138: 1327-1338, 2015, Lim, Y.Y., et al. in Alzheimer's Dementia 9: 538-545, 2013], but there are no reports using non-linear mixed effect model for amyloid plaque progression over time similar to that existing of disease-modifying biomarkers for other diseases [Cook, S.F. and R.R. Bies in Current Pharmacol Rep 2: 221-230, 2016, Gueorguieva, I., et al. in Alzheimer's Dementia 19: 2253-2264, 2023]. This study describes the natural progression of amyloid accumulation with population mean and between-participant variability for baseline and intrinsic progression rates quantified across the AD spectrum. 1340 ADNI participants were followed over a 10-year period with

Indexed as

Alzheimer DiseasePlaque, AmyloidAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrainDisease ProgressionFemaleHumansMaleMiddle AgedPositron-Emission TomographyAmyloid beta-PeptidesBiomarkersADNIAmyloid accumulation covariatesBiomarker progression modelingNatural amyloid plaque accumulation

Identifiers

PMID39862333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.